You will play an integral role in the function of a busy clinical trials unit with >30 studies ranging from phase I-III across lymphoma, myeloma and leukaemia. We have an active cellular therapy program including autologous and allogeneic CAR T-cell trials.

Post-doctoral position to study the “Oncogenic deregulation of early human Lymphoid Lineage Specification”

The Biomedical Excellence for Safer Transfusion (BEST) Collaborative is an international research organization whose objective is to improve the safety of transfusion and cell therapy and related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in haemotherapy and cell therapy.

We have received Cancer Research UK funding for an exciting programme of work, which aims to transform our understanding of how leukaemia cells adapt to the CNS microenvironment and use this information to design new treatment approaches.